Indication
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
Loading your page…
Loading your page…
Immune System Diseases
Marketing Authorisation Holder: Swedish Orphan Biovitrum AB (publ)
INN: emapalumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Gamifant: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.